Endocrine Abstracts

Backgroud: When considering treatment of patients with severe osteoporosis (after previously failed antiresorptive treatment) or patients with glucocorticoid–induced osteoporosis, it is suitable to choose treatment by teriparatide (TPTD, rhPTH 1–34). In contrast to long–term treatment by bisphosphonates (BP) or denosumab (DMAB), the treatment with TPTD increases the volume of trabecular bone and the thickness of cortical bone. The recommended length of treatm...

Parathyroid hormone (PTH) has a biphasic effect on bone cells and can induce opposing responses resulting in both net bone loss and net bone formation. Patients with primary hyperparathyroidism (PHPT) lose the circadian rhythm for PTH and bone mass decreases. PTH administered intermittently resulting in increase in bone mass. We studied the differences in the circadian variability of bone turnover markers between women with PHPT and women with postmenopausal osteoporosis treat...

Our understanding of modifiable risk factors for developing primary hyperparathyroidism (PHPT) may support interventions to prevent the development of the disease or reduce its severity and deepen our insights into its pathogenesis. Obesity has been associated with elevated serum parathyroid hormone (PTH) in the general population and may also alter the clinical presentation in patients with PHPT.Objectives: The objectives of the study were to compare th...